Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ open, 2022 - bmjopen.bmj.com
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results
T Kato, T Seto, M Nishio, K Goto, N Yamamoto… - Drug safety, 2018 - Springer
Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - European Journal of Medical Research, 2023 - Springer
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an …
H Saito, T Fukuhara, N Furuya, K Watanabe… - The Lancet …, 2019 - thelancet.com
Background Resistance to first-generation or second-generation EGFR tyrosine kinase
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small …
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small …
BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of …
C Gridelli, A Rossi, F Ciardiello, F De Marinis… - Clinical Lung Cancer, 2016 - Elsevier
Background About 20% of advanced non–small-cell lung cancer (NSCLC) cases harbor
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR …
Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
[HTML][HTML] EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity …
Background Recent study showed that the combination of erlotinib and bevacizumab had
better disease control than erlotinib monotherapy in patients with advanced epidermal …
better disease control than erlotinib monotherapy in patients with advanced epidermal …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
相关搜索
- plus bevacizumab cell lung
- meta analysis erlotinib alone
- lung cancer erlotinib alone
- lung cancer meta analysis
- erlotinib alone in patients
- lung cancer bevacizumab in patients
- plus bevacizumab propensity score
- meta analysis combination with bevacizumab
- plus bevacizumab egfr tki
- lung cancer egfr mutations
- cell lung egfr tki
- cell lung propensity score
- egfr mutations bevacizumab in patients
- survival in patients effect of erlotinib
- meta analysis erlotinib in combination